We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Over the last 18 months, the pendulum has swung back to aggressive FDA enforcement of cGMPs for medical devices, Mark Brown, a partner with King & Spalding, said last month at the FDAnews Fourth Annual Medical Device Quality Congress.